Nonshared Hetero Atoms In At Least Two Rings Of The Polycyclo Ring System Patents (Class 514/81)
-
Publication number: 20120122818Abstract: Methods and compositions are provided for treating lung diseases, including but not limited to infections and small cell and non-small cell lung cancer, by conjugating a drug of interest to glycerol ethers or glycerol phosphate ethers.Type: ApplicationFiled: January 18, 2012Publication date: May 17, 2012Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Karl Y. Hostetler, James R. Beadle
-
Publication number: 20120108547Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.Type: ApplicationFiled: December 22, 2011Publication date: May 3, 2012Applicant: Pharmacyclics, Inc.Inventors: Orion D. Jankowski, James T. Palmer, Lee Honigberg
-
Publication number: 20120107323Abstract: The invention provides compounds capable of treating a subject suffering from or being susceptible to a cell proliferative disorder (especially, cancer), methods of identifying and using the compounds, pharmaceutical compositions and kits thereof.Type: ApplicationFiled: March 12, 2010Publication date: May 3, 2012Applicant: University of FloridaInventors: Steven N. Hochwald, David A. Ostrov, William G. Cance, Elena Kurenova
-
Patent number: 8168615Abstract: This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein: X is C or N with the proviso that when X is N, R1 does not exist; W is C or N with the proviso that when W is N, R2 does not exist; V is C; E is hydrogen or a pharmaceutically acceptable salt thereof; and Y is selected from the group consisting of Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein: L and M are independently selected from the group consisting of C1-C6 alkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.Type: GrantFiled: April 26, 2010Date of Patent: May 1, 2012Assignee: Bristol-Myers Squibb CompanyInventors: Yasutsugu Ueda, Timothy P. Connolly, John F. Kadow, Nicholas A. Meanwell, Tao Wang, Chung-Pin H. Chen, Kap-Sun Yeung, Zhongxing Zhang, David Kenneth Leahy, Shawn K. Pack, Nachimuthu Soundararajan, Pierre Sirard, Kathia Levesque, Dominique Thoraval
-
Publication number: 20120101065Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.Type: ApplicationFiled: December 22, 2011Publication date: April 26, 2012Applicant: Pharmacyclics, Inc.Inventors: Orion D. Jankowski, James T. Palmer, Lee Honigberg
-
Publication number: 20120101064Abstract: The invention provides compounds of the formula (I): and salts, tautomers, solvates and N-oxides thereof; wherein Q is CH or N; X is N, N+—O? or CR3; Y is N, N+—O? or CR3a; R1 and R2 are independently selected from hydrogen and various substituents as defined in the claims; or R1 and R2 together with the atoms to which they are attached, link to form an optionally substituted carbocyclic or heterocyclic aromatic or non-aromatic ring of 4 to 7 members; R3 is selected from hydrogen and various substituents; and R3a is selected from hydrogen and various substituents as defined in the claims. Also provided are pharmaceutical compositions containing the compounds of formula (I), processes for making the compounds and the medical uses of the compounds. The compounds of formula (I) have activity as inhibitors of CDK kinases and are useful in the treatment of inter alia proliferative diseases such as cancers.Type: ApplicationFiled: April 30, 2010Publication date: April 26, 2012Applicants: Astex Therapeutics Limited, Novartis AGInventors: Steven Howard, Paul Neil Mortenson, Steven Douglas Hiscock, Alison Jo-Anne Woolford, Andrew James Woodhead, Gianni Chessari, Marc O'reilly, Miles Stuart Congreve, Claudio Dagostin, Young Shin Cho, Fan Yang, Christine Hiu-Tung Chen, Christopher Thomas Brain, Bharat Lagu, Yaping Wang, Sunkyu Kim, John Grialdes, Michael Joseph Luzzio, Lawrence Blas Perez
-
Patent number: 8163718Abstract: Novel compounds having structure (1) wherein Z, is N or CH to form a purine, Y, R1, R2? and R2 are defined in the specification, are provided for use in the treatment of tumors and the prophylaxis or treatment of viral infections.Type: GrantFiled: February 19, 2009Date of Patent: April 24, 2012Assignee: Gilead Sciences, Inc.Inventors: Gabriel Birkus, Adrian S. Ray, Daniel B. Tumas, William J. Watkins
-
Patent number: 8163719Abstract: The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.Type: GrantFiled: July 5, 2011Date of Patent: April 24, 2012Assignee: Johns Hopkins University School of MedicineInventors: Philip A. Beachy, James K. Chen, Anssi Jussi Nikolai Taipale
-
Publication number: 20120095455Abstract: Photochemical tissue bonding methods include the application of a photosensitizer to a tissue, e.g., cornea, followed by irradiation with electromagnetic energy to produce a tissue seal. The methods are useful for wound repair, or other tissue repair.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: The General Hospital CorporationInventors: Robert W. Rodmond, Irene E. Kochevar, Dimitri Azar
-
Publication number: 20120083470Abstract: Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-mediated diseases or conditions or tyrosine kinase-dependent diseases or conditions are provided.Type: ApplicationFiled: October 5, 2011Publication date: April 5, 2012Applicant: Pharmacyclics, Inc.Inventors: Orion D. Jankowski, James T. Palmer, Lee Honigberg
-
Publication number: 20120077772Abstract: The present invention relates to the oral solid pharmaceutical composition comprising lamivudine or a pharmaceutically acceptable salt thereof with isomalt as a filler. The present invention also relate to the combination of lamivudine and other Anti-HIV agents. Thus, for example, the present invention provides a stable tablet formulation comprising lamivudine, isomalt, crospovidone, calcium stearate and opadry white.Type: ApplicationFiled: May 27, 2009Publication date: March 29, 2012Applicant: HETERO RESEARCH FOUNDATIONInventors: Bandi Parthasaradhi Reddy, Male Srinivas Reddy, Pothireddy Venkateswar Reddy, Muppidi Vanaja Kumari
-
Publication number: 20120077781Abstract: The present invention relates novel flavin derivatives and other flavin derivatives, their use and compositions for use as riboswitch ligands and/or anti-infectives. The invention also provides method of making novel flavin derivatives.Type: ApplicationFiled: August 11, 2009Publication date: March 29, 2012Inventors: Robert Gadwood, Harpreet Kaur, Kevin Kells, Jeffrey A. Leiby, David Moon, Vinh Pham, Philip D.G. Coish, Kenneth F. Blount, Brian R. Dixon, Jayhyuk Myung, David Osterman, Stephanie Avola, Nick Baboulas, Angelica Bello, Judd Berman, Bruce R. Evans, Tan Quach, Heinrich J. Schostarez, Frank C. Sciavolino, Dennis Underwood, Phil Wickens, Jeffrey Wilson, Justin Wu
-
Patent number: 8138164Abstract: The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections.Type: GrantFiled: October 19, 2007Date of Patent: March 20, 2012Assignee: Merck Sharp & Dohme Corp.Inventors: Nigel J. Liverton, Vincenzo Summa, Joseph P. Vacca
-
Publication number: 20120058097Abstract: The invention generally relates to compositions including a sodium channel blocker and a B vitamin molecule and methods of use thereof. In certain embodiments, the invention provides compositions that include a sodium channel blocker and a B vitamin molecule. In other embodiments, the invention provides methods for treating a subject having a psychological disorder, a neurological disorder, a neurodengerative disorder, and/or a disorder associated with pain involving administering to the subject a sodium channel blocker and a B vitamin molecule.Type: ApplicationFiled: September 2, 2011Publication date: March 8, 2012Applicant: MS THERAPEUTICS LIMITEDInventors: Michael J. Hudson, Alan Michael Palmer
-
Publication number: 20120058975Abstract: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.Type: ApplicationFiled: August 29, 2011Publication date: March 8, 2012Inventors: Karl Y. Hostetler, James R. Beadle, Ganesh D. Kini
-
Publication number: 20120053147Abstract: This invention relates to novel compounds of formula (I): and derivatives thereof useful for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3? OH kinase family (hereinafter PI3 kinases), suitably, PI3K?, PI3K}, PI3K?, and/or PI3K?.Type: ApplicationFiled: May 20, 2010Publication date: March 1, 2012Inventors: Hong Lin, Juan I Luengo, Ralph A. Rivero, Mark James Schulz, Ren Xie, Jin Zeng
-
Publication number: 20120046246Abstract: This invention relates to therapeutic methods for treating or preventing an osteoclast-related disease or disorder in a subject identified as in need of a treatment of bone diseases, compounds for such uses, and compositions thereof.Type: ApplicationFiled: December 18, 2009Publication date: February 23, 2012Applicant: University of Florida Research FoundationInventors: Lexie Shannon Holliday, David A. Ostrov
-
Publication number: 20120040924Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV in human patients or other animal hosts. The compounds are certain 6-substituted purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1, HIV-2, HCV, Norovirus, Saporovirus, HSV-1, HSV-2, Dengue virus, Yellow fever, and HBV.Type: ApplicationFiled: February 9, 2010Publication date: February 16, 2012Applicants: EMORY UNIVERSITY, RFS PHARMA, LLC.Inventors: Jong Hyun Cho, Steven J. Coats, Raymond F. Schinazi, Hongwang Zhang, Longhu Zhou
-
Patent number: 8114994Abstract: Provided are cyclobutyl nucleosides and methods for their use in treatment of infections including Retroviridae (including HIV), Hepadnaviridae (including HBV), or Flaviviridae (including BVDV and HCV) infection, or conditions related to abnormal cellular proliferation, in a host, including animals, and especially humans.Type: GrantFiled: February 10, 2009Date of Patent: February 14, 2012Assignee: Emory UniversityInventors: Dennis C. Liotta, Shuli Mao, Michael Hager, Raymond F Schinazi
-
Publication number: 20120035115Abstract: The invention features compounds of formula I or II: In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression.Type: ApplicationFiled: September 23, 2009Publication date: February 9, 2012Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Muthiah Manoharan, Kallanthottathil G. Rajeev, Takeshi Yamada, David Butler, K. Narayanannair Jayaprakash, Muthusamy Jayraman, Shigeo Matsuda, Rajendra K. Pandey, Chang Geng Peng
-
Publication number: 20120028925Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.Type: ApplicationFiled: May 25, 2011Publication date: February 2, 2012Applicant: ABBOTT LABORATORIESInventors: Zhi-Fu Tao, Xilu Wang, Andrew J. Souers, Nathaniel D. Catron, Gerard M. Sullivan
-
Publication number: 20120015908Abstract: A compound of Formula I is disclosed as follows: or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R is hydrogen, P(?O)(OH)2, P(?O)(O(C1-C18)alkylene(C6-C20)aryl)2, P(?O)(OH)(OM), P(?O)(OM)2, P?O(O2M), S(?O)(OH)2, S(?O)(O(C1-C18)alkylene(C6-C20)aryl)2, S(?O)(OH)(OM), S(?O)(OM)2; M is a monovalent or divalent metal ion, or alkylammonium ion; W is (C6-C20)aryl, (C6-C20)heteroaryl, (C1-C18)alkyl(C6-C20)aryl, (C1-C18)alkyl(C6-C20)heteroaryl, hydroxy(C6-C20)aryl, hydroxy(C6-C20)heteroaryl, (C1-C18)alkoxy(C6-C20)aryl, (C1-C18)alkoxy(C6-C20)heteroaryl, (C1-C18)alkylenedioxy(C6-C20)aryl, (C1-C18)alkylenedioxy(C6-C20)heteroaryl, halo(C6-C20)aryl, halo(C6-C20)heteroaryl, (C1-C18)alkylamino(C6-C20)aryl, (C1-C18)alkylamino(C6-C20)heteroaryl, (C1-C18)cycloalkylamino(C6-C20)aryl, or (C1-C18)cycloalkylamino(C6-C20)heteroaryl, and their OR8 substutes; R5 is (C1-C18alkoxy, hydrogen, hydroxyl, O—(C1-C18)alkyl(C6-C20)aryl, halo or OR8, or R5 and R6 are (C1-C18)dioxy provided that R7 iType: ApplicationFiled: July 13, 2011Publication date: January 19, 2012Applicant: Efficient Pharma Management CorporateInventors: Sheng-Chu Kuo, Kuo-Hsiung Lee, Li-Jiau Huang, Li-Chen Chou, Tian-Shung Wu, Tzong-Der Way, Jing-Gung Chung, Jai-Sing Yang, Chi-Hung Huang, Meng-Tung Tsai
-
Publication number: 20120015907Abstract: The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: April 19, 2011Publication date: January 19, 2012Applicant: NOVARTIS AGInventors: David BARNES, Rajiv CHOPRA, Scott Louis COHEN, Jiping FU, Mitsunori Kato, Peichao LU, Mohindra SEEPERSAUD, Wei ZHANG
-
Publication number: 20120010171Abstract: The present invention provides: 1) Derivative solid form of 9-[2-(R)-[bis[pivaloyloxymethoxy]-phosphinylmethoxy]propyl]adenine (bis-POM PMPA, abbreviated as TD hereinafter), including crystalline form A and form B of TD, TD fumarate salts and cyclodextrin inclusion complex of TD; 2) Synthesis and purification methods of TD and Solidification method of TD oil, including converting TD oil to crystalline TD in Form A and Form B, solid TD salts and cyclodextrin inclusion complex of TD; 3) Stable pharmaceutical compositions containing TD derivatives and their preparation; 4) The use of the above TD derivatives in the antiviral treatments, especially in the treatment of HIV, HBV, CMV, HSV-1, HSV-2 and human Herpes virus infections.Type: ApplicationFiled: June 27, 2011Publication date: January 12, 2012Applicants: JIANGSU CHIA TAI TIANQING PHARMACEUTICAL CO., LTD., BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD.Inventor: JIANDONG YUAN
-
Publication number: 20120009247Abstract: Provided in some embodiments are compositions comprising a compound having a structure according to Formula A or Formula B: or a pharmaceutically acceptable salt, tautomer or hydrate thereof, where X2 is a bond or linker, X3 is bond or —PO4—, and X1, R1, R2, R3, and n are described herein. Also provided in some embodiments are methods for making and using such compounds and compositions.Type: ApplicationFiled: April 29, 2011Publication date: January 12, 2012Inventors: Roberto Maj, Franco Pattarino, Emanuela Mura, Alcide Barberis
-
Publication number: 20120010170Abstract: A conjugate compound comprising an acyclic nucleoside phosphonate covalently coupled to a lipid for the therapeutic and/or prophylactic treatment of viral infection in an immunodeficient subject is described, along with compositions and methods of using the same. A preferred conugate compound is CMX001, having formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: April 25, 2008Publication date: January 12, 2012Inventor: George R. Painter
-
Publication number: 20120009150Abstract: The present invention relates to pharmaceutical compositions for treating virus infections and/or diseases caused by virus infections comprising at least a diaryl urea compound optionally combined with at least one additional therapeutic agent. Useful combinations include e.g. BAY 43-9006 as a diaryl urea compound.Type: ApplicationFiled: September 20, 2011Publication date: January 12, 2012Inventors: Olaf WEBER, Bernd Riedl
-
Patent number: 8093229Abstract: Alkynyl pyrrolo [2,3-d] pyrimidines of Formula I are described and demonstrated to have utility as Heat Shock Protein 90 (HSP90) inhibiting agents used in the treatment and prevention of various HSP90 mediated disorders. Methods of synthesis and use of such compounds are also described and claimed.Type: GrantFiled: May 22, 2009Date of Patent: January 10, 2012Assignee: Conforma Therapeutics CorporationInventors: Srinivas Rao Kasibhatla, Marco Antonio Biamonte, Jiandong Shi, Marcus F. Boehm
-
Patent number: 8088754Abstract: Compounds and compositions of Formula I are described, useful as anti-proliferative agents, and in particular anti-HPV, wherein: Y1A and Y1B are independently Y1; RX1 and RX2 are independently RX; Y1 is ?O, —O(RX), ?S, —N(RX), —N(O)(RX), —N(ORX), —N(O)(ORX), or —N(N(RX)(RX)); and pharmaceutically acceptable salts thereof.Type: GrantFiled: February 18, 2009Date of Patent: January 3, 2012Assignee: Gilead Sciences, Inc.Inventors: Xiaoqin Cheng, Gary P. Cook, Gong-Xin He, Choung U. Kim, John C. Rohloff, Jianying Wang, Zheng-Yu Yang
-
Patent number: 8076373Abstract: The present invention provides a method for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof. The method comprises contacting the mammalian cells with a therapeutically effective amount of a reactive oxygen species mediator, wherein the reactive oxygen species mediator is selected from the group consisting of pyruvates, pyruvate precursors, ?-keto acids having four or more carbon atoms, precursors of ?-keto acids having four or more carbon atoms, and the salts thereof, wherein mediation of reactive oxygen species results in mediation of peroxynitrous acid. The present invention further provides a pharmaceutical composition for treating wounds and diseases in mammals, caused by mammalian cells involved in an inflammatory response, by altering indigenous in vivo levels of peroxynitrous acid, and salts thereof.Type: GrantFiled: February 11, 2005Date of Patent: December 13, 2011Assignee: North Cell PharmaceticalInventor: Alain Martin
-
Publication number: 20110301125Abstract: Provided herein are novel and useful methods for preventing, treating, or ameliorating a macular degeneration such as dry macular degeneration, wet macular degeneration and age related macular degeneration in a patient.Type: ApplicationFiled: December 18, 2009Publication date: December 8, 2011Applicant: SANOFI-AVENTISInventor: Chang Hahn
-
Patent number: 8071609Abstract: This invention relates to compounds of the general formula: in which Q is an ethynyl or ethenyl moiety; Ring A is an aryl, heteroaryl or heterocyclic ring or ring system; and the remaining variable groups are as defined herein, and to their preparation and use.Type: GrantFiled: August 11, 2006Date of Patent: December 6, 2011Assignee: ARIAD Pharmaceuticals, Inc.Inventors: Yihan Wang, Wei-Sheng Huang, Rajeswari Sundaramoorthi, Xiaotian Zhu, R. Mathew Thomas, William C. Shakespeare, David C. Dalgarno, Tomi K. Sawyer
-
Publication number: 20110293521Abstract: Certain embodiments disclosed relate to compositions, including therapeutic compositions, methods, articles of manufacture, systems, and devices. Certain embodiments relate to anti-viral compositions, methods, articles of manufacture, systems and devices.Type: ApplicationFiled: May 28, 2010Publication date: December 1, 2011Inventors: Roderick A. Hyde, Muriel Y. Ishikawa, Jordin T. Kare, Eric C. Leuthardt, Lowell L. Wood, JR., Victoria Y.H. Wood
-
Publication number: 20110288054Abstract: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.Type: ApplicationFiled: September 22, 2009Publication date: November 24, 2011Applicant: Schering CorporationInventors: Bandarpalle B. Shankar, Seong Heon Kim, Wensheng Yu, Ling Tong, Michael K.C. Wong, Brian J. Lavey, Joseph A. Kozlowski, Lei Chen, Razia K. Rizvi, Aneta Maria Kosinski, De-Yi Yang, Guowei Zhou, Kristen E. Rosner, Luke Fire, Judson E. Richard, Dansu Li
-
Publication number: 20110286962Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.Type: ApplicationFiled: May 26, 2011Publication date: November 24, 2011Inventors: Jean-Pierre SOMMADOSSI, Gilles Gosselin, Claire Pierra, Christian Perigaud, Suzanne Peyrottes
-
Patent number: 8063028Abstract: Compounds of formula I, wherein R1, R2, R3, X1, X2 and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.Type: GrantFiled: December 22, 2008Date of Patent: November 22, 2011Assignee: Roche Palo Alto LLCInventors: Roland Joseph Billedeau, Zachary Kevin Sweeney
-
Publication number: 20110281821Abstract: The invention relates to compounds of Formula (I), a polymorph, an enantiomer, a stereoisomer, a solvate, an N-oxide derivative, or a pharmaceutically acceptable salt thereof: Formula (I), which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.Type: ApplicationFiled: January 30, 2008Publication date: November 17, 2011Applicant: Biogen Idec MA Inc.Inventors: Srinivas Rao Kasibhatla, Kevin Hong, Lin Zhang, Marcus F. Boehm, Junhua Fan, Jean-Yves LeBrazidec
-
Publication number: 20110269675Abstract: A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular hone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).Type: ApplicationFiled: July 14, 2011Publication date: November 3, 2011Inventors: Christian HANSEN, Henrik NILSSON, Stephan CHRISTGAU, Henry G. BONE, III
-
Publication number: 20110263535Abstract: A tyrosine-based (phosphonylmethoxyalkyl)purine or -pyrimidine conjugate is provided. In some embodiments, the conjugate includes tyrosine based amino acid or dipeptide moieties of (S)-9-(3-hydroxy-2-phosphonyl-methoxypropyl)adenine or its cytosine analogue. A method of synthesizing such conjugates based on Boc-protected amino acid or dipeptides is also provided. In addition, a method of isomerizing an (S,S)-diastereoisomer to an (S,R)-diastereoisomer of an amino acid-based or dipeptide-based conjugate by a process including transesterification is provided. A method of inhibiting viral infection and a method of treating viral infection based on (phosphonylmethoxyalkyl)purine or -pyrimidine conjugates is also provided.Type: ApplicationFiled: April 23, 2011Publication date: October 27, 2011Inventors: Charles E. McKenna, Boris A. Kashemirov, Ivan S. Krylov, Michaela Serpi, Valeria M. Zakharova, Larryn W. Peterson, John M. Hilfinger
-
Publication number: 20110263534Abstract: The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.Type: ApplicationFiled: August 11, 2006Publication date: October 27, 2011Inventors: Yannick Stephane Rose, Stephane Ciblat, Ting Kang, Adel Rafai Far, Evelyne Dietrich, Yanick Lafontaine, Ranga Reddy
-
Publication number: 20110257100Abstract: This invention relates to compounds that inhibit protein tyrosine kinase activity. In particular the invention relates to compounds that inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signaling, for example, the inhibition of VEGF receptor signaling. The invention also provides compounds, compositions and methods for treating cell proliferative diseases and conditions and ophthalmic diseases, disorders and conditions.Type: ApplicationFiled: April 8, 2011Publication date: October 20, 2011Inventors: Stëphane Raeppel, Franck Raeppel, Stephen William Claridge, Lijie Zhan, Frëdëric Gaudette, Michael Mannion, Norifumi Sato, Yohei Yuki, Masashi Kishida, Arkadii Vaisburg
-
Publication number: 20110257111Abstract: This invention relates to novel hydroxyethylamino sulfonamides and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a compound with the ability to act as an HIV (human immunodeficiency virus) protease inhibitor.Type: ApplicationFiled: October 23, 2009Publication date: October 20, 2011Inventors: Scott L. Harbeson, Carig E. Masse
-
Publication number: 20110244027Abstract: The present invention relates to 2?-Fluoro-6?-methylene carbocyclic nucleosides, pharmaceutical compositions containing these nucleosides and their use in the treatment or prophylaxis of a number of viral infections and secondary disease states and conditions thereof, especially including Hepatitis B virus (HBV) and secondary disease states and conditions thereof (cirrhosis and liver cancer), Heptatitis C virus (HCV), Herpes Simplex virus I and II (HSV-1 and HSV-2), cytomegalovirus (CMV), Varicella-Zoster Virus (VZV) and Epstein Barr virus (EBV) and secondary cancers which occur thereof (lymphoma, nasopharyngeal cancer, including drug resistant (especially including lamivudine and/or adefovir resistant) and other mutant forms of these viruses.Type: ApplicationFiled: May 13, 2011Publication date: October 6, 2011Applicant: University of Georgia Research CenterInventors: Chung K. Chu, Jianing Wang
-
Publication number: 20110237525Abstract: A method of supplementing a diet and ameliorating oxidative stress in a mammal includes administering a pharmaceutically effective amount of lipid soluble, hydrophobic active compounds having a chemical structure: wherein R1 is an aromatic backbone and R2 is a sulfur containing ligand. Through formation of disulfide linkages other moieties can be attached to R2 converting the hydrophobic base into a water soluble entity, for ease of delivery, which can be reconverted back to the original compound by biochemical reduction in the blood stream.Type: ApplicationFiled: June 18, 2010Publication date: September 29, 2011Inventors: Boyd E. Haley, Niladri Narayan Gupta
-
Publication number: 20110236485Abstract: Drugs are formulated as oral dosage forms for controlled release in which the release rate limiting portion is a shell surrounding the drug-containing core. The shell releases drug from the core by permitting diffusion of the drug from the core. The shell also motes gastric retention of the dosage form by swelling upon imbibition of gastric fluid to size that is retained in the stomach during the postprandial or fed mode.Type: ApplicationFiled: June 8, 2011Publication date: September 29, 2011Applicant: DEPOMED, INC.Inventors: BRET BERNER, Jenny Louie-Helm, Gloria Gusler, John N. Shell
-
Publication number: 20110237549Abstract: Provided is a computer model generated from a data array, computer readable storage media encoded with the model, and computers comprising the model, wherein the model is derived from atomic structure coordinates of a FMN riboswitch or a lysine riboswitch. Further provided is a pharmacophore having a spatial arrangement of atoms defined by the binding pocket identified in the model, along with a compound defined by the pharmacophore. Also further provided are methods for rational drug design based on the atomic structure data, and compounds identified by the rational drug design process.Type: ApplicationFiled: March 27, 2009Publication date: September 29, 2011Applicant: MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Dinshaw Patel, Alexander Serganov, Lili Huang
-
Publication number: 20110237550Abstract: Novel 5-azaindole bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.Type: ApplicationFiled: September 22, 2009Publication date: September 29, 2011Applicant: ISIS INNOVATION LTD.Inventors: Frank Hallock Ebetino, Adam Mazur, Mark Walden Lundy, Robert Graham Russell
-
Publication number: 20110224277Abstract: Compounds, compositions and methods are provided for modulating the expression and function of small non-coding RNAs. The compositions comprise oligomeric compounds, targeted to small non-coding RNAs. Methods of using these compounds for modulation of small non-coding RNAs as well as downstream targets of these RNAs and for diagnosis and treatment of disease associated with small non-coding RNAs are also provided.Type: ApplicationFiled: December 31, 2008Publication date: September 15, 2011Applicant: REGULUS THERAPEUTICS, LLC.Inventors: Christine Esau, Bridget Lollo, C. Frank Bennett, Susan M. Freier, Richard H. Griffey, Brenda F. Baker, Timothy A. Vickers, Eric G. Marcusson, Erich Koller, Eric E. Swayze, Ravi Jain, Balkrishen Bhat, Eigen Peralta
-
Publication number: 20110224172Abstract: Substituted 1-oxa-2,8-diaza-spiro[4,5]dec-2-ene compounds and processes for their production, the use thereof for producing pharmaceutical compositions, pharmaceutical compositions containing these compounds and methods of treatment using these compounds.Type: ApplicationFiled: May 26, 2011Publication date: September 15, 2011Applicant: GRUENENTHAL GmbHInventors: Heinrich Helmut BUSCHMANN, Guenter Werner Englberger, Tieno Germann, Hagen-Heinrich Hennies, Corinna Maul, Bernd Sundermann, Joerg Holenz
-
Publication number: 20110212924Abstract: Phosphonate and phosphinate N-methanocarba derivatives of AMP including their prodrug analogs are described. MRS2339, a 2-chloro-AMP derivative containing a (N)-methanocarba (bicyclo[3.1.0]hexane) ring system in place of ribose, activates P2X receptors, ligand-gated ion channels. Phosphonate analogues of MRS2339 were synthesized using Michaelis-Arbuzov and Wittig reactions, based on the expectation of increased half-life in vivo due to the stability of the C—P bond. When administered to calsequestrin-overexpressing mice (a genetic model of heart failure) via a mini-osmotic pump (Alzet), some analogues significantly increased intact heart contractile function in vivo, as assessed by echocardiography-derived fractional shortening (FS) as compared to vehicle-infused mice. The range of carbocyclic nucleotide analogues for treatment of heart failure has been expanded.Type: ApplicationFiled: February 22, 2011Publication date: September 1, 2011Inventors: Bruce Liang, Kenneth A. Jacobson, Bhalchandra V. Joshi, Thatikonda Santhosh Kumar